AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Phathom Pharmaceuticals Inc (NASDAQ:PHAT)
10.37 USD
+0.100 0.974%Sponsored Reports
Loading...
| Previous Close (in USD) | 10.27 |
|---|---|
| Change | +0.100 0.974% |
| 52 W H/L (in USD) | 17.019/6.065 |
| EBITDA (in USD) | -206.546M |
| PE Ratio | -- |
| Volume | 554282 |
| Diluted Eps TTM | -4.37 |
| Total Assets (in USD) | 413.842M |
|---|---|
| Total Liabilities (in USD) | 486.601M |
| Revenue TTM (in USD) | 2.594M |
| Cash (in USD) | 381.393M |
| Market Cap (in USD) | 602.327 M |
| Revenue Per Share TTM | 0.047 |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Employees: 452
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Ms. Terrie J. Curran | Pres, CEO & Director | 1969 |
| 2. | Mr. David A. Socks | Co-Founder & Director | 1975 |
| 3. | Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder & COO | 1960 |
| 4. | Mr. Anthony J. Guzzo | Chief Accounting Officer | 1973 |
| 5. | Mr. Aditya Kohli Ph.D. | Co-Founder | 1988 |
| 6. | Ms. Molly Henderson CPA, MBA | Chief Financial & Bus. Officer | 1971 |
| 7. | Mr. Joseph Hand J.D. | Chief Admin. Officer | NA |
| 8. | Mr. Lawrence Miller Esq., J.D. | Gen. Counsel & Sec. | NA |
| 9. | Mr. Tom Harris | Chief Devel. Sciences Officer | NA |
| 10. | Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.080 0.182% | 43.94 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.990 4.737% | 44 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.115 0.026% | 440.02 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.660 0.108% | 613.11 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -197.723M | -143.883M | -129.068M | -255.131M | -1.288M |
| Minority Interest | - | - | - | - | - |
| Net Income | -223.006M | -148.094M | -133.318M | -209.744M | -1.288M |
| Selling General Administrative | 100.999M | 62.742M | 27.517M | 6.944M | 1.205M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 0.62M | 0.521M | 0.323M | 0.008M | - |
| Ebit | -172.44M | -135.08M | -125.665M | -106.215M | -1.225M |
| Ebitda | -170.418M | -137.095M | -124.582M | -154.682M | -1.275M |
| Depreciation And Amortization | 2.022M | -2.015M | 1.083M | -48.467M | -0.05M |
| Operating Income | -172.44M | -135.08M | -125.665M | -106.215M | -1.225M |
| Other Operating Expenses | 172.44M | 135.08M | 125.665M | 106.215M | 1.225M |
| Interest Expense | 27.305M | 6.788M | 4.581M | 4.177M | 0.013M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 2.132M | 0.041M | 1.091M | 1.089M | 0M |
| Net Interest Income | -25.173M | -6.747M | -3.49M | -3.088M | -0.013M |
| Income Tax Expense | 25.283M | 4.211M | 4.25M | -45.387M | 0.013M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 172.44M | 135.08M | 125.665M | 106.215M | 1.225M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | -25.283M | -8.803M | -3.403M | -148.916M | -0.05M |
| Net Income From Continuing Ops | -197.723M | -143.883M | -129.068M | -255.131M | -1.288M |
| Net Income Applicable To Common Shares | -197.723M | -143.883M | -129.068M | -255.131M | -1.288M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 413.842M | 164.81M | 189.431M | 295.111M | 257.178M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 13.194M | 5.127M | 3.267M | 3.872M | 11.836M |
| Total Liab | 486.601M | 239.624M | 117.275M | 100.84M | 29.223M |
| Total Stockholder Equity | -72.759M | -74.814M | 72.156M | 194.271M | 227.955M |
| Other Current Liab | 7.111M | 15.532M | 13.284M | 30.915M | 0.413M |
| Common Stock | 0.005M | 0.003M | 0.003M | 0.003M | 0.002M |
| Capital Stock | 0.005M | 0.003M | 0.003M | 0.003M | 0.002M |
| Retained Earnings | -928.685M | -727.093M | -529.37M | -385.487M | -256.419M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.804M | 0.341M | 2.757M | 0.181M |
| Cash | 381.393M | 155.385M | 183.259M | 287.496M | 243.765M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 38.781M | 26.237M | 18.921M | 55.524M | 3.748M |
| Current Deferred Revenue | 18.343M | - | - | - | 2.475M |
| Net Debt | -242.363M | -58.315M | -91.918M | -238.478M | -220.192M |
| Short Term Debt | 0.726M | 0.708M | 0.487M | 7.827M | 0.161M |
| Short Long Term Debt | - | - | - | 7.353M | - |
| Short Long Term Debt Total | 139.03M | 97.07M | 91.341M | 49.018M | 23.573M |
| Other Stockholder Equity | 855.921M | 652.276M | 601.523M | 579.755M | 484.372M |
| Property Plant Equipment | - | 3.494M | 0.65M | 3.359M | 1.396M |
| Total Current Assets | 397.432M | 160.512M | 186.526M | 291.368M | 255.601M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 1.637M | - | - | 0.082M | - |
| Long Term Debt | 137.842M | 95.264M | 89.671M | 39.634M | 22.777M |
| Inventory | 1.208M | - | - | -0.082M | - |
| Accounts Payable | 12.601M | 9.997M | 5.15M | 16.782M | 0.699M |
| Accumulated Other Comprehensive Income | 0M | - | - | - | -0.008M |
| Non Currrent Assets Other | 9.926M | 0.804M | 0.341M | 0.384M | 0.181M |
| Non Current Assets Total | 16.41M | 4.298M | 2.905M | 3.743M | 1.577M |
| Capital Lease Obligations | 1.188M | 1.806M | 1.67M | 2.031M | 0.796M |
| Long Term Debt Total | - | - | 89.671M | 39.634M | 22.777M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -1.041M | -0.328M | -1.04M | -25.25M | 0M |
| Total Cashflows From Investing Activities | -1.041M | -0.328M | -1.04M | -25.25M | -25.25M |
| Total Cash From Financing Activities | 120.042M | 44.708M | 114.459M | 304.646M | 1.902M |
| Net Income | -197.723M | -143.883M | -129.068M | -255.131M | -1.288M |
| Change In Cash | -27.529M | -104.237M | 43.731M | 242.886M | 0.879M |
| Begin Period Cash Flow | 183.419M | 287.496M | 243.765M | 0.879M | 0M |
| End Period Cash Flow | 155.89M | 183.259M | 287.496M | 243.765M | 0.879M |
| Total Cash From Operating Activities | -146.53M | -148.617M | -69.688M | -36.51M | -1.023M |
| Depreciation | 0.62M | 0.521M | 0.323M | 0.008M | 0.008M |
| Other Cashflows From Investing Activities | - | - | - | -25.118M | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | 1.944M | 0.629M | 191.472M | 0.002M |
| Other Cashflows From Financing Activities | 95.446M | 97.543M | 25.629M | 113.174M | 1.9M |
| Capital Expenditures | 1.041M | 0.328M | 1.04M | 25.25M | 0.132M |
| Change In Working Capital | 5.438M | -27.475M | 51.717M | -9.522M | 0.215M |
| Other Non Cash Items | 21.002M | 5.408M | 1.595M | 131.457M | 0.05M |
| Free Cash Flow | -147.571M | -148.945M | -70.728M | -61.76M | -1.023M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Invesco Global A | 2 years ago | 1723301 |
| 2. | Invesco OFI Global Equity | 2 years ago | 1723301 |
| 3. | PGIM Jennison Health Sciences Z | 2 years ago | 1490560 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1225999 |
| 5. | Jennison Health Sciences Equity | 2 years ago | 892270 |
| 6. | iShares Russell 2000 ETF | 2 years ago | 741840 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 524653 |
| 8. | Simplify Propel Opportunities ETF | 2 years ago | 521935 |
| 9. | MEDICAL BioHealth EUR Acc | 2 years ago | 436943 |
| 10. | Invesco VI Global I | 2 years ago | 393078 |
| 11. | JNL/Invesco Global Growth A | 2 years ago | 331538 |
| 12. | Fidelity Small Cap Index | 2 years ago | 325167 |
| 13. | Eagle Small Cap Core Inst'l | 2 years ago | 304839 |
| 14. | Strategic Advisers Small-Mid Cap | 2 years ago | 229213 |
| 15. | iShares Russell 2000 Value ETF | 2 years ago | 222448 |
| 16. | APO Medical Opportunities R | 2 years ago | 216600 |
| 17. | BrighthouseI Invesco Global Equity A | 2 years ago | 216312 |
| 18. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 198444 |
| 19. | Fidelity Extended Market Index | 2 years ago | 194585 |
| 20. | iShares Biotechnology ETF | 2 years ago | 188614 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Medicxi Ventures Management (Jersey) Ltd | 2 years ago | 3760869 |
| 2. | The Carlyle Group Inc | 2 years ago | 3496808 |
| 3. | Amvescap Plc. | 2 years ago | 3167653 |
| 4. | BlackRock Inc | 2 years ago | 2678891 |
| 5. | Ensign Peak Advisors Inc | 2 years ago | 2280000 |
| 6. | Vanguard Group Inc | 2 years ago | 1979113 |
| 7. | NEA Management Company, LLC | 2 years ago | 1960169 |
| 8. | Avidity Partners Management LP | 2 years ago | 1735000 |
| 9. | Jennison Associates LLC | 2 years ago | 1647697 |
| 10. | Gilder Gagnon Howe & CO LLC | 2 years ago | 1455132 |
| 11. | 683 Capital Management LLC | 2 years ago | 1280000 |
| 12. | Woodline Partners LP | 2 years ago | 1096121 |
| 13. | Decheng Capital LLC | 2 years ago | 850000 |
| 14. | Geode Capital Management, LLC | 2 years ago | 735273 |
| 15. | Catalys Pacific LLC | 2 years ago | 721962 |
| 16. | State Street Corporation | 2 years ago | 687837 |
| 17. | Kennedy Capital Management Inc | 2 years ago | 571976 |
| 18. | GW&K Investment Management, LLC | 2 years ago | 561490 |
| 19. | Saturn V Capital Management LLC | 2 years ago | 500987 |
| 20. | Ghost Tree Capital, LLC | 2 years ago | 485000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...